Stock Markets June 9, 2026 01:00 PM

Boots owners in talks over possible $10 billion sale, London IPO may be set aside

Sycamore Partners has opened strategic-sale discussions that could pre-empt a planned London flotation, report says

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
SIG

Boots is reportedly the subject of advanced discussions about a potential roughly $10 billion sale involving the Weston family and Australian pharmacy group Sigma Healthcare, a development that could derail previously considered plans for a London initial public offering. Private equity owner Sycamore Partners began engaging potential strategic buyers before Easter and has progressed talks with the Canadian branch of the Weston family. Owners had been conducting a strategy review that included the possibility of an IPO as early as 2027, as well as the option to sell.

Boots owners in talks over possible $10 billion sale, London IPO may be set aside
SIG
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Boots is in talks about a potential sale valued at approximately $10 billion involving the Weston family and Sigma Healthcare - impacts retail and healthcare sectors.
  • Private equity owner Sycamore Partners began discussions with strategic buyers before Easter and has progressed negotiations with the Canadian branch of the Weston family.
  • Owners were conducting a strategy review that included the possibility of a London IPO as early as 2027, but the sale option was also being considered - relevant to equity markets and investment banking activity.

Boots, the UK pharmacy and retail chain, is in negotiations that could lead to a sale valued at about $10 billion, according to a report citing people familiar with the matter. The discussions involve the Weston family and Sigma Healthcare, the Australian pharmacy group, and may remove a London initial public offering from consideration.

Private equity firm Sycamore Partners, which purchased the parent company Walgreens Boots Alliance last year in a transaction valued at $10 billion and took control of Boots, began holding conversations with potential strategic buyers before Easter, the report said.

Those discussions have reportedly moved forward with the Canadian branch of the Weston family. That branch holds investments in retail and pharmacy businesses through Wittington Investments, including stakes in grocery chain Loblaws and pharmacy chain Shoppers Drug Mart.

In April, another news report said Boots’ owners were working with advisers on a strategic review that included preparing for a possible London initial public offering as early as 2027. That same review also kept the option of a sale on the table, leaving both routes under consideration for the company’s owners.

Boots operates more than 1,800 stores across Britain and offers a combination of pharmacy services, health products and beauty brands, among them Soap & Glory. The retailer is a significant provider of pharmacy services funded by the National Health Service.

The discussions over a prospective sale and the parallel strategy review mean the company’s path - whether toward a public listing in London or a private sale - remains unsettled. The outcome could determine ownership and strategic direction, although no definitive deal has been announced in the reporting referenced.


Context and next steps

According to the reports, Sycamore Partners initiated outreach to prospective strategic buyers before Easter and has since engaged the Weston family’s Canadian arm. The strategic review conducted by Boots’ owners continued to weigh an IPO timetable alongside the sale option, indicating owners have been examining both private and public exits.

Risks

  • A sale could preclude a London IPO, removing a potential public-market exit and affecting capital markets activity - relevant to equity capital markets and investment banking.
  • Ongoing negotiations may not result in a transaction, leaving the company’s ownership and strategic direction uncertain - relevant to retail and healthcare service continuity.
  • Timing and outcome remain uncertain due to the parallel strategy review, which keeps both sale and IPO options open and may prolong stakeholder uncertainty - relevant to investors and suppliers in retail and pharmacy sectors.

More from Stock Markets

Anthropic unveils Claude Fable 5 with layered safeguards; Mythos 5 released for trusted defenders Jun 9, 2026 Philips-Sponsored Survey Finds AI Boosts Clinician Productivity and Cuts Costs Jun 9, 2026 BTIG Flags REITs as Poised for Breakout Amid Momentum Weakness in High-Flying Sectors Jun 9, 2026 Salesforce conducts another round of layoffs, trims teams tied to AI and cloud products Jun 9, 2026 Tesla Shares Slide as SpaceX IPO, Product Delays and Market Retreat Weigh on Stock Jun 9, 2026